RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
IX Biopharma Stock

IX Biopharma Stocks 2024

IX Biopharma Stocks

767.36 M

Ticker

42C.SI

ISIN

SG1BD9000009

In 2024, IX Biopharma had 767.36 M outstanding stocks, a -0.8% change from the 773.57 M stocks in the previous year.

The IX Biopharma Stocks history

YEARNUMBER OF STOCKS (undefined SGD)
2025e767.36
2024767.36
2023773.57
2022754.63
2021695.25
2020655.16
2019651.67
2018649.36
2017646.18
2016602.65
2015522.54
2014545.68
2013545.68
2012545.68

IX Biopharma shares outstanding

The number of shares was IX Biopharma in 2023 — This indicates how many shares 773.566 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IX Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IX Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IX Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IX Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IX Biopharma Aktienanalyse

What does IX Biopharma do?

IX Biopharma Ltd is a leading biopharmaceutical company based in Singapore. The company was founded in 2007 by Dr. Jan-Olof Heldin, a globally recognized biotech entrepreneur. The history of IX Biopharma dates back to the late 90s, when Dr. Heldin began working on a new method of drug delivery called "Oral Transmucosal Technology" (OTM). This technology allows for the development of drugs that can quickly and specifically penetrate the body, with a very high bioavailability. Today, IX Biopharma has a strong presence in the market for novel OTM-based drugs. The company operates in three different business areas: human medicine products, animal health, and life sciences. IX Biopharma's human medicine products are specialized in the treatment of pain and inflammation. The company has already launched a product - a fast-acting spray for pain relief. This new technology allows the medication to quickly enter the body and take effect, providing patients with rapid pain relief. IX Biopharma is currently working on additional products based on OTM technology to provide suitable solutions for other medical conditions as well. In the animal health sector, IX Biopharma offers veterinary products tailored to the needs of pets and livestock. The company collaborates closely with veterinarians and livestock experts to develop innovative therapies and treatment methods customized for specific animal needs. In the field of life sciences, IX Biopharma engages in a wide range of activities and services. These include the development of diagnostic products, conducting clinical trials, identifying biomarkers, and developing immunotherapies. Overall, IX Biopharma is an innovative biopharmaceutical company specializing in the development of drugs based on new technologies. The company is constantly striving to find innovative solutions to improve the health of humans and animals. With a dedicated team of scientists and researchers, as well as a strong presence in Asia and Europe, IX Biopharma is a pioneer in the new world of OTM-based drug development. IX Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating IX Biopharma's Shares Outstanding

IX Biopharma's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in IX Biopharma’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding IX Biopharma’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in IX Biopharma’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about IX Biopharma stock

How many stocks are there of IX Biopharma?

The current number of stocks of IX Biopharma is 767.36 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of IX Biopharma are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of IX Biopharma evolved in recent years?

The number of shares of IX Biopharma has increased by -0.8% gesunken compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. IX Biopharma as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of IX Biopharma?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does IX Biopharma pay?

Over the past 12 months, IX Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IX Biopharma is expected to pay a dividend of 0 SGD.

What is the dividend yield of IX Biopharma?

The current dividend yield of IX Biopharma is .

When does IX Biopharma pay dividends?

IX Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IX Biopharma?

IX Biopharma paid dividends every year for the past 0 years.

What is the dividend of IX Biopharma?

For the upcoming 12 months, dividends amounting to 0 SGD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IX Biopharma located?

IX Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von IX Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IX Biopharma from 10/6/2024 amounting to 0 SGD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did IX Biopharma pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of IX Biopharma in the year 2023?

In the year 2023, IX Biopharma distributed 0 SGD as dividends.

In which currency does IX Biopharma pay out the dividend?

The dividends of IX Biopharma are distributed in SGD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von IX Biopharma

Our stock analysis for IX Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IX Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.